There is a lack of effective pharmacotherapy for NAFLD treatment; however, anti-obesity medications and agents modulating insulin resistance, including GLP-1, are used for the management of NAFLD [136,138]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.